Evidence map›Paper›PMID 41541686›Full record

ArticleiScience2026

Chidamide: Exploration of maintenance therapy for patients with DLBCL with HBV infection.

Ying Zhang, Haotian Wang, Wei Guo, Yangzhi Zhao, Zhumei Zhan, Zhe Li, Bowen Wang, Ou Bai

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04661943 (Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04661943 phase2completednot on this map

Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma

TypeinterventionalSponsorOu Bai, MD/PHDRan2017 to 2024Enrolled30ConditionsDiffuse Large B-cell LymphomaArmsTucidinostat
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ying ZhangDepartment of Hematology, The First Hospital of Jilin University, Changchun, China.
Haotian WangDepartment of Hematology, The First Hospital of Jilin University, Changchun, China.
Wei GuoDepartment of Hematology, The First Hospital of Jilin University, Changchun, China.
Yangzhi ZhaoDepartment of Hematology, The First Hospital of Jilin University, Changchun, China.
Zhumei ZhanDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China.
Zhe LiDepartment of Hematology, The First Hospital of Jilin University, Changchun, China.
Bowen WangDepartment of Hematology, The First Hospital of Jilin University, Changchun, China.
Ou BaiDepartment of Hematology, The First Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B virus (HBV) infection worsens the prognosis of patients with diffuse large B-cell lymphoma (DLBCL), possibly through epigenetic mechanisms. We conducted a prospective, single-arm, open-label clinical trial (NCT04661943) to evaluate the efficacy and safety of chidamide maintenance therapy in patients with HBV+ DLBCL who achieved complete or partial response after first-line treatment. Seventy patients with HBV+ were enrolled, including 30 receiving chidamide (20 mg twice weekly for two years) and 40 controls who declined treatment, with a propensity score-matched HBV- cohort for comparison. Chidamide maintenance significantly improved progression-free survival (

Indexed as

MicrobiologyViral microbiology

Identifiers

PMID41541686
PMCPMC12800633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.